Unique ID issued by UMIN | UMIN000004071 |
---|---|
Receipt number | R000004525 |
Scientific Title | Long-term therapeutic effect of pioglitazone on chronic kidney disease (CKD) |
Date of disclosure of the study information | 2010/08/20 |
Last modified on | 2025/03/09 21:07:29 |
Long-term therapeutic effect of pioglitazone on chronic kidney disease (CKD)
Long-term treatment of CKD by pioglitazone.
Long-term therapeutic effect of pioglitazone on chronic kidney disease (CKD)
Long-term treatment of CKD by pioglitazone.
Japan |
chronic kidney disease (CKD)
Nephrology |
Others
NO
To evaluate the long-term proteinuria-reducing and reno-protective effect of pioglitazone on non-diabetic chronic kidney disease
Efficacy
Confirmatory
Explanatory
Not applicable
Inhibition of deterioration in renal function (serum creatinine, estimated GFR)
Decrease in levels of proteinuria
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
YES
NO
YES
2
Treatment
Medicine |
Patients of intervention group are treated with pioglitazone orally from the dose of 15mg/day, increasecd to the continuous dose of 15-45mg/day within one month, and continued for 3 years. The efficacy and side effects are evaluated.
Patients of control group are treated with pioglitazone dipyridamole orally from the dose of 150mg/day, increasecd to the continuous dose of 300mg/day within one month, and continued for 3 years. The efficacy and side effects are compared with intervention group.
18 | years-old | <= |
85 | years-old | >= |
Male and Female
Non-diabetic chronic kidney disease with proteinuria of 0.3g/day (1+ by test tape) or more.
1. Chronic renal failure with serum creatinine level above 3.0 mg/dl.
2. Severe liver dysfunction.
3. Severe edema or chronic heart failure.
4. Past history of allergy against pioglitazone.
5. Pregnant or breast feeding patients.
6. Patients with ongoing steroid therapy.
50
1st name | |
Middle name | |
Last name | Hiroo Kumagai |
National Defense Medical College
Department of Nephrology
3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
1st name | |
Middle name | |
Last name | Takashi Oda |
National Defense Medical College
Department of Nephrology
3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
04-2995-1609
takashio@ndmc.ac.jp
National Defense Medical College
None
Self funding
NO
防衛医科大学校病院(埼玉県)
2010 | Year | 08 | Month | 20 | Day |
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000004525
Unpublished
https://center6.umin.ac.jp/cgi-open-bin/icdr/ctr_view.cgi?recptno=R000004525
0
Short-term (6 months) treatment effects of the study were announced at the Japanese Society of Nephrology in June 2010 that, although there was no improvement in renal function in the pioglitazone group, there was a slight reduction in proteinuria. Therefore, this study was planned to investigate the long-term treatment effects, but at the same time there were reports of side effects caused by pioglitazone, and patient enrollment did not progress at all, so the study was discontinued.
2025 | Year | 03 | Month | 09 | Day |
Because Dr. Oda, who was in charge of the research contact, was transferred from the National Defense Medical College to the Tokyo Medical University Hachioji Medical Center, reporting became delayed.
The study was discontinued.
The study was discontinued.
The study was discontinued.
The study was discontinued.
The study was discontinued.
The study was discontinued.
Preinitiation
2010 | Year | 08 | Month | 20 | Day |
2010 | Year | 08 | Month | 01 | Day |
2014 | Year | 10 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2015 | Year | 01 | Month | 01 | Day |
2015 | Year | 03 | Month | 01 | Day |
2010 | Year | 08 | Month | 19 | Day |
2025 | Year | 03 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004525